Active Pharmaceutical Ingredient Market

Active Pharmaceutical Ingredient Market worth $238.3 billion by 2029

The report "Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (captive, merchant), Synthesis (Synthetic, Biotech), Products (mAb, Hormones, Cytokines), Drug (OTC, Rx), Application (Diabetes, oncology, CVD) - Global Forecast to 2029", is projected to reach USD 238.3 billion by 2029 from USD 163.5 billion in 2024, at a CAGR of 7.8% during the forecast period of 2024 to 2029. The growth of this market is driven by increasing demand for active pharmaceutical ingredients in research and development of novel therapeutics, collaborations between academic institutions, research organizations, and industry players to develop innovative APIs. Additionally, continuous advancements in API manufacturing technologies, and automation have led to improved precision, efficiency of API.

Browse 692 market data Tables and 65 Figures spread through 562 Pages and in-depth TOC on "Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (captive, merchant), Synthesis (Synthetic, Biotech), Products (mAb, Hormones, Cytokines), Drug (OTC, Rx), Application (Diabetes, oncology, CVD) - Global Forecast to 2029"
View detailed Table of Content here -

The traditional API segment accounted for the largest share, by potency in the active pharmaceutical ingredients market in 2023.

By product, the active pharmaceutical ingredients market is segmented into traditional API and highly potent API. Traditional APIs include low-potency, medium-potency, and potent APIs. Low-potency APIs form category I of the SafeBridge classification system. In 2023, the traditional APIs segment accounted for the largest share of the active pharmaceutical ingredients market. This can be attributed to increasing application across a range of therapeutic areas, the growing uptake of these APIs in biopharmaceuticals, and advancements in manufacturing processes that are driving segment growth.

The synthetic APIs segment accounted for the largest share of the synthesis segment in the active pharmaceutical ingredients market in 2023.

Based on synthesis, the global active pharmaceutical ingredients market has been segmented into synthetic APIs and innovative APIs. The synthetic APIs segment held the largest market share in 2023. The large share of this segment can be attributed to the growing number of regulatory approvals for new drugs and technological advancements in synthesis methods. Synthetic APIs offer certain advantages over large molecules. They can be engineered to deliver a strong therapeutic effect in small doses, often below 10 mg up to microgram levels. The requirement for smaller amounts of APIs, coupled with advancements in chemical manufacturing technologies, makes them low-cost, high-efficacy products as compared to large-molecule therapeutics. Moreover, the analytical techniques used for developing small molecules are highly refined, thus ensuring high quality, efficacy, and reproducibility.

The North American region catered to the largest share of the active pharmaceutical ingredients market in 2023.

The North America market has experienced significant growth in recent years, showing an expansion growth, due to presence of the large pharmaceutical & biopharmaceutical industry in the region, the increase in R&D expenditure, strict country regulations, and the presence of majority of key players of active pharmaceutical ingredients products in the US and Canada. Additionally, growth of the North American active pharmaceutical ingredients market is driven by significant factors such as a multitude of ongoing cancer research and clinical trials, the expansion of the biosimilars and generics sector, and the increasing adoption of outsourcing preclinical, clinical, and manufacturing services by pharmaceutical and biopharmaceutical companies.

Key players in the active pharmaceutical ingredients market include Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), GSK PLC (UK), Sanofi (France), Viatris Inc. (US),  Divi's Laboratories Limited (India), Sandoz Group AG (Switzerland), Boehringer Ingelheim International GmBH (US), SK Inc. (US), Eli Lilly and Company (US), Merck KGaA (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals PLC (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Aburaihan Pharmaceutical Company (Iran), Curia Global, Inc. (US), Cambrex Corporation (US), API Pharma Tech (US), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), Hovione (Portugal), ChemCon GmbH (Germany), and Pharco (Egypt).

Don’t miss out on business opportunities in Active Pharmaceutical Ingredient Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Active Pharmaceutical Ingredient Market Size,  Share & Growth Report
Report Code
PH 1262
PR Published ON
Choose License Type
Request Customization
Speak to Analyst
Speak to Analyst
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
  • What are the Known and Unknown Adjacencies Impacting the Active Pharmaceutical Ingredient Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
©2024 MarketsandMarkets Research Private Ltd. All rights reserved Protection Status

Digital Virtual Assistant - MarketsandMarkets